Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 4 271-282, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Long-term cancer patient survival in the United States

PA Wingo, LA Ries, SL Parker and CW Heath Jr
Epidemiology and Surveillance Research Department, American Cancer Society, Atlanta, Georgia 30329-4251, USA.

Although survival rates are useful for monitoring progress in the early detection and treatment of cancer and are of particular interest to patients with new diagnoses, there are limited population-based estimates of long-term survival rates. We used data collected by the Surveillance, Epidemiology, and End Results Program for cases diagnosed during 1974-1991 and followed through 1992 to estimate relative survival at 5, 10, and 15 years after diagnosis of cancer of the breast, prostate, colon and rectum, and lung. Relative survival after diagnosis of breast and prostate cancer continued to decline up through 15 years after diagnosis, whereas survival after diagnosis of lung and colon or rectal cancer remained approximately constant after 5 and 10 years, respectively. Age-specific patterns of survival varied by site, stage, and demographics. Among patients with localized breast and prostate cancer, women who were younger than age 45 at breast cancer diagnosis and men who were 75 years and older at prostate cancer diagnosis had the poorest relative survival. Relative survival among lung cancer patients decreased with age at diagnosis, regardless of stage or demographics, and age-specific patterns of relative survival for patients with cancer of the colon and rectum differed according to race. Among white patients diagnosed with cancers of the colon and rectum, relative survival did not vary by age at diagnosis; among black patients older than 45 at diagnosis, relative survival decreased with age. This study provides population-based estimates of long-term survival and confirms black/white, male/female, and stage- and age-specific differences for the major cancers.

This article has been cited by other articles:

				B. A. Rybicki, C. Neslund-Dudas, C. H. Bock, A. Rundle, A. T. Savera, J. J. Yang, N. L. Nock, and D. Tang Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate and Biochemical Recurrence after Prostatectomy Clin. Cancer Res., February 1, 2008; 14(3): 750 - 757. [Abstract] [Full Text] [PDF]

				V. B. Stull, D. C. Snyder, and W. Demark-Wahnefried Lifestyle Interventions in Cancer Survivors: Designing Programs That Meet the Needs of This Vulnerable and Growing Population J. Nutr., January 1, 2007; 137(1): 243S - 248S. [Abstract] [Full Text] [PDF]

				J. Gu, D. Berman, C. Lu, I. I. Wistuba, J. A. Roth, M. Frazier, M. R. Spitz, and X. Wu Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7329 - 7338. [Abstract] [Full Text] [PDF]

				W. Demark-Wahnefried, B. M. Pinto, and E. R. Gritz Promoting Health and Physical Function Among Cancer Survivors: Potential for Prevention and Questions That Remain J. Clin. Oncol., November 10, 2006; 24(32): 5125 - 5131. [Abstract] [Full Text] [PDF]

				W. Demark-Wahnefried, E. C. Clipp, M. C. Morey, C. F. Pieper, R. Sloane, D. C. Snyder, and H. J. Cohen Lifestyle Intervention Development Study to Improve Physical Function in Older Adults With Cancer: Outcomes From Project LEAD J. Clin. Oncol., July 20, 2006; 24(21): 3465 - 3473. [Abstract] [Full Text] [PDF]

				H. Sugimura and P. Yang Long-term Survivorship in Lung Cancer: A Review. Chest, April 1, 2006; 129(4): 1088 - 1097. [Abstract] [Full Text] [PDF]

				S. Buckley, W. Shi, B. Driscoll, A. Ferrario, K. Anderson, and D. Warburton BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells Am J Physiol Lung Cell Mol Physiol, January 1, 2004; 286(1): L81 - L86. [Abstract] [Full Text] [PDF]

				K. S. Garman, C. F. Pieper, P. Seo, and H. J. Cohen Function in Elderly Cancer Survivors Depends on Comorbidities J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1119 - 1124. [Abstract] [Full Text] [PDF]

				J. K. Brown, T. Byers, C. Doyle, K. S. Courneya, W. Demark-Wahnefried, L. H. Kushi, A. McTiernan, C. L. Rock, N. Aziz, A. S. Bloch, et al. Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices CA Cancer J Clin, September 1, 2003; 53(5): 268 - 291. [Abstract] [Full Text]

				V. Cohen, V. Panet-Raymond, N. Sabbaghian, I. Morin, G. Batist, and R. Rozen Methylenetetrahydrofolate Reductase Polymorphism in Advanced Colorectal Cancer: A Novel Genomic Predictor of Clinical Response to Fluoropyrimidine-based Chemotherapy Clin. Cancer Res., May 1, 2003; 9(5): 1611 - 1615. [Abstract] [Full Text] [PDF]

				C. C. Earle, H. J. Burstein, E. P. Winer, and J. C. Weeks Quality of Non-Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors J. Clin. Oncol., April 15, 2003; 21(8): 1447 - 1451. [Abstract] [Full Text] [PDF]

				E. P. Mitchell Prognosis After Rectal Cancer Treatment in Blacks and Whites: Advanced Stage at Diagnosis or Other Factors? J. Clin. Oncol., February 1, 2003; 21(3): 397 - 398. [Full Text] [PDF]

				H. Brenner and T. Hakulinen Advanced Detection of Time Trends in Long-term Cancer Patient Survival: Experience from 50 Years of Cancer Registration in Finland Am. J. Epidemiol., September 15, 2002; 156(6): 566 - 577. [Abstract] [Full Text] [PDF]

				A. D. McCollum, P. J. Catalano, D. G. Haller, R. J. Mayer, J. S. Macdonald, A. B. Benson III, and C. S. Fuchs Outcomes and Toxicity in African-American and Caucasian Patients in a Randomized Adjuvant Chemotherapy Trial for Colon Cancer J Natl Cancer Inst, August 7, 2002; 94(15): 1160 - 1167. [Abstract] [Full Text] [PDF]

				T. N. Chirikos, T. Hazelton, M. Tockman, and R. Clark Screening for Lung Cancer With CT* : A Preliminary Cost-effectiveness Analysis Chest, May 1, 2002; 121(5): 1507 - 1514. [Abstract] [Full Text] [PDF]

				H. Brenner and T. Hakulinen Up-to-Date Long-Term Survival Curves of Patients With Cancer by Period Analysis J. Clin. Oncol., February 1, 2002; 20(3): 826 - 832. [Abstract] [Full Text] [PDF]

				E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, M. Jahn, et al. Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study J. Clin. Oncol., November 1, 2001; 19(21): 4097 - 4106. [Abstract] [Full Text] [PDF]

				S. Toyooka, K. O. Toyooka, R. Maruyama, A. K. Virmani, L. Girard, K. Miyajima, K. Harada, Y. Ariyoshi, T. Takahashi, K. Sugio, et al. DNA Methylation Profiles of Lung Tumors Mol. Cancer Ther., November 1, 2001; 1(1): 61 - 67. [Abstract] [Full Text] [PDF]

				J. M. Silva, G. Dominguez, J. Silva, J. M. Garcia, A. Sanchez, O. Rodriguez, M. Provencio, P. Espana, and F. Bonilla Detection of Epithelial Messenger RNA in the Plasma of Breast Cancer Patients Is Associated with Poor Prognosis Tumor Characteristics Clin. Cancer Res., September 1, 2001; 7(9): 2821 - 2825. [Abstract] [Full Text] [PDF]

				P. M. Hoff, R. Ansari, G. Batist, J. Cox, W. Kocha, M. Kuperminc, J. Maroun, D. Walde, C. Weaver, E. Harrison, et al. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study J. Clin. Oncol., April 15, 2001; 19(8): 2282 - 2292. [Abstract] [Full Text] [PDF]

				D. C. Hodgson, C. S. Fuchs, and J. Z. Ayanian Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer J Natl Cancer Inst, April 4, 2001; 93(7): 501 - 515. [Abstract] [Full Text] [PDF]

				A. C. Voogd, M. Nielsen, J. L. Peterse, M. Blichert-Toft, H. Bartelink, M. Overgaard, G. van Tienhoven, K. W. Andersen, R. J. Sylvester, and J. A. van Dongen Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials J. Clin. Oncol., March 15, 2001; 19(6): 1688 - 1697. [Abstract] [Full Text] [PDF]

				J. R. Thornbury, D. K. Ornstein, P. L. Choyke, C. P. Langlotz, and J. C. Weinreb Prostate Cancer: What Is the Future Role for Imaging? Am. J. Roentgenol., January 1, 2001; 176(1): 17 - 22. [Full Text]

				X. q. Chen, H. Bonnefoi, M.-F. Pelte, J. Lyautey, C. Lederrey, S. Movarekhi, P. Schaeffer, H. E. Mulcahy, P. Meyer, M. Stroun, et al. Telomerase RNA as a Detection Marker in the Serum of Breast Cancer Patients Clin. Cancer Res., October 1, 2000; 6(10): 3823 - 3826. [Abstract] [Full Text]

				T. RUTHERFORD, W. D. BROWN, E. SAPI, S. ASCHKENAZI, A. MUNOZ, and G. MOR Absence of Estrogen Receptor-{beta} Expression in Metastatic Ovarian Cancer Obstet. Gynecol., September 1, 2000; 96(3): 417 - 421. [Abstract] [Full Text] [PDF]

				D. Strassheim, S. H. Shafer, S. H. Phelps, and C. L. Williams Small Cell Lung Carcinoma Exhibits Greater Phospholipase C-{beta}1 Expression and Edelfosine Resistance Compared with Non-Small Cell Lung Carcinoma Cancer Res., May 1, 2000; 60(10): 2730 - 2736. [Abstract] [Full Text]

				X. q. Chen, H. Bonnefoi, S. Diebold-Berger, J. Lyautey, C. Lederrey, E. Faltin-Traub, M. Stroun, and P. Anker Detecting Tumor-related Alterations in Plasma or Serum DNA of Patients Diagnosed with Breast Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2297 - 2303. [Abstract] [Full Text] [PDF]